Wockhardt

Wockhardt is an antibiotics research-based global pharmaceutical and biotech company that operates with over 2,900 employees from 27 different nationalities across various countries. The company's core purpose is simple: to save lives globally and sustainably by tackling one of humanity's most urgent threats, which is antimicrobial resistance. Having developed deep expertise, Wockhardt has the complete capability to manage the entire process from discovering a new drug to its development and commercialization. The company has successfully developed and sold important biotechnology products like Hepatitis-B vaccines, human insulin, and treatments for anaemia, which are well-received in the market. Wockhardt has a significant business footprint in Europe and India, with about 78% of its total global income coming from its international operations. Uniquely, it is the only company globally to receive special 'Qualified Infectious Disease Product' status from the USFDA for six of its anti-bacterial drugs.;